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Abstract
Alzheimer’s disease (AD) is a neurodegenerative disorder characterised by a slow progres-
sive deterioration of cognitive capacity. Drugs are urgently needed for the treatment of AD
and unfortunately almost all clinical trials of AD drug candidates have failed or been discon-
tinued to date. Mathematical, computational and statistical tools can be employed in the
construction of clinical trial simulators to assist in the improvement of trial design and
enhance the chances of success of potential new therapies. Based on the analysis of a set
of clinical data provided by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) we
developed a simple stochastic mathematical model to simulate the development and pro-
gression of Alzheimer’s in a longitudinal cohort study. We show how this modelling frame-
work could be used to assess the effect and the chances of success of hypothetical
treatments that are administered at different stages and delay disease development. We
demonstrate that the detection of the true efficacy of an AD treatment can be very challeng-
ing, even if the treatment is highly effective. An important reason behind the inability to
detect signals of efficacy in a clinical trial in this therapy area could be the high between- and
within-individual variability in the measurement of diagnostic markers and endpoints, which
consequently results in the misdiagnosis of an individual’s disease state.
Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder which is characterised by progres-
sive accumulation of amyloid-beta (Aβ) peptides, forming senile plaques in the brain, and neu-
rofibrillary tangles of hyperphosphorylated tau, followed by progressive neuronal and synaptic
loss. It has long preclinical and prodromal stages and affects memory, thinking, behaviour,
daily functional abilities, and emotion. Alzheimer’s disease may account for approximately
60–80% of dementia cases [1]. The worldwide prevalence of dementia was estimated to be
over 46 million people, with studies suggesting that the number of cases is rising exponentially
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with age and that the above estimate will almost triple by 2050 [2–4]. Apart from the health
and social problems, Alzheimer’s, and dementias in general, have huge economic impact, with
the estimated worldwide cost of dementia approaching USD 818 billion [4–6]. Thus, drugs are
urgently needed to improve therapies of AD and dementia.
There are two competing models proposed to explain the hallmarks of AD: the amyloid
hypothesis (the neuron-centric model) [7, 8] and the Inverse Warburg hypothesis (the neu-
ron-astrocytic model) [9, 10]. The neuron-centric model suggests that a mutation in the
nuclear genome induce overproduction of Aβ and tau that become toxic to neurons. The neu-
ron-astrocytic model contends that the progression of AD is triggered by defects in the normal
energy transduction process, a condition induced by mitochondrial dysregulation. Although
some clinical trials of metabolic interventions have shown promising results for the improve-
ment of cognitive performance [11, 12], clinical trials of disease-modifying treatments have
consistently failed. A recent study reviewed 413 clinical trials (124 Phase 1 trials, 206 Phase 2
trials, and 83 Phase 3 trials) of AD drug candidates that have been conducted between 2002
and 2012 [13]. The study reported that 99.6% of the trials failed or had been discontinued. No
cure or other treatments that prevent, halt or reverse the underlying pathology of established
AD have been approved as yet. Available treatments, such as the cholinesterase inhibitors tac-
rine (1993), donepezil (1996), rivastigmine (1998) and galantamine (2001), are approved for
mild to moderate AD and can provide only temporary improvement in cognitive and beha-
vioural symptoms, and at best a temporary impact on the progression of the underlying
pathology of the disease [14].
The failure rate of AD clinical trials is far higher than that of trials in other therapy areas,
and information on the reasons of trial failure or discontinuation is limited [13, 15]. Some of
the reasons of high trial failure include the poorly understood nature of AD pathogenesis and
progression and poor trial design. For example, the wrong choice of clinical endpoints and
markers used as clinical trial entry criteria, as well as the selection of unsuitable individuals for
enrolment in the trial. The retention of participants due to the long duration of the AD trials is
also an important problem to overcome in the design of successful clinical trials in the AD
area [15]. The high failure rate of clinical trials can also be attributed to the inability to detect
signals of efficacy, even if the treatment is safe and effective. This could be due to the adminis-
tration of the drug at a relatively late stage of the disease, at which time the condition of the
patient may be irreversible, or due to the high variability in the measurements of different bio-
chemical and cognitive markers that are used as diagnostic markers and endpoints.
Mathematical modelling of AD progression and the development of clinical trial simula-
tions are essential tools for exploring the reasons why a clinical trial can fail and for the
improvement of the design of clinical trials. The poorly understood nature of AD pathogenesis
and progression limits the possibilities of developing robust mechanistic models for the accu-
rate prediction of disease progression. However, a few attempts have been made to develop
models that describe the development of AD at the molecular level (e.g. [16–20]). Published
mathematical models also include semi-mechanistic models developed to describe longitudi-
nal changes in measures of cognition, as assessed by errors in various cognitive tests designed
for the assessments of the cognitive capabilities of the patients, such as the Modified Mini-
Mental State Examination (MMSE) and the Alzheimer’s Disease Assessment Scale (ADAS-
cog) [21–25]. In general, published research on the mathematical modelling of AD has mainly
focused on: (1) the study of the epidemiology of AD (e.g. [26, 27]); (2) the investigation of the
progression of the disease based on changes in the cognitive status (e.g. [21–25]); (3) on defin-
ing the order of the various biomarkers of the disease in predicting progression (e.g. [28–40]),
and (4) on the description of the pathogenesis and evolution of the disease at the molecular
level (e.g. [16–20]). Most of the models developed so far are stochastic in nature [41]. Such
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models permit variability in the model parameters and chance elements in AD disease
progression.
In this study we develop and analyse a simple stochastic model to predict AD progression
in a clinical trial. In particular, we define a discrete-time Markov model to describe the move-
ment of individuals through a finite sequence of distinct health and disease states over time
(distinct time points at which the state of the individuals is assessed). Markov models are ideal
for the modelling of AD, as this disorder can be described as a multi-state disease process, and
due to the observational nature of studies of AD in which the condition of individuals is
assessed at periodic visits. These are also useful tools for the estimation of the impact of risk
factors on the transitions between the states and can easily include reversible states that have
been observed in many AD cohort studies. This modelling framework can contribute to the
improved design of future clinical trials by providing insights into what to measure, the impor-
tance of measurement error in determining efficacy, sample size selection, duration of the trial
and other important factors such as demographic characteristics of the sample. Markov mod-
els have also been purposed in previous studies for the estimation of the probabilities of transi-
tioning between different stages of AD severity, and the investigation of potential covariates
that can influence these probabilities [14, 41–51]. In this study, we use this framework to
develop tools for the assessment and evaluation of the impact of receiving a hypothetical pre-
ventative treatment of varying efficacy, at different stages of disease progression, and illustrate
the potential problems detecting significant differences between treated and untreated individ-
uals. The specific action of the treatments in the model is irrelevant; the treatments are
assumed to reduce the probability of transitioning to a more severe stage of the disease, which
consequently slows the development and progression of the disease.
The transition probability distributions of the Markov model we describe are estimated
using a particular longitudinal cohort dataset provided by the Alzheimer’s Disease Neuroimag-
ing Initiative (ADNI, adni.loni.usc.edu).
Material and methods
The model
The development and progression of AD in a clinical trial was assumed to be a stochastic pro-
cess. In particular, we developed a discrete-time Markov chain in a random environment
defined on a finite state space, with the property that for all states the probability of moving
from the current state to the next state is independent of the past. Individuals were classified
according to their disease status. In particular, based on a set of criteria individuals were cate-
gorised as Cognitively Normal (CN), with Mild Cognitive Impairment (MCI) and with AD.
The criteria are based on the level or presence of a number of markers, including but not lim-
ited to memory complaints, logical memory II subscale, MMSE, CDR, and NINCDS/ADRDA
criteria for probable AD [52]. The states are distinct and do not overlap.
In each (discrete) time step of the process, individuals can either withdraw from the study,
for example due to death or personal reasons, remain at the same state or move to a different
state with some probability (transition probability). Based on the information obtained from
the ADNI dataset, transitions are allowed between the states CN and MCI in both directions
(i.e. recovery to normal cognition is also allowed) and from the MCI to the AD state. Back-
transitions may be due to either measurement error or a genuine ability in some patients to
show cognitive improvement (e.g. due to cognitive reserve). In the ADNI dataset, a small num-
ber of transitions from AD back to MCI is also observed (a total of 17 transitions in yearly
assessments across the ten-year cohort). Some reverse transitions from AD to MCI, as well as
from MCI back to CN, have also been recorded in other longitudinal studies [50, 53–56].
Modelling Alzheimer’s disease
PLOS ONE | https://doi.org/10.1371/journal.pone.0190615 January 29, 2018 3 / 19
However, due to the progressive nature of AD and the fact that AD diagnosis cannot be con-
firmed until an autopsy is performed, in the theoretical model that we developed we do not
allow transitions from AD back to MCI state, i.e. once patients reach the AD state their condi-
tion cannot improve. Even in the presence of candidate treatments that could potentially
reverse the pathology at a stage of AD (e.g. [57, 58]), there is no sufficient evidence that the
cognitive functions and clinical outcome of AD individuals can be improved. Due to the sto-
chastic nature of the model, allowing both an MCI to CN and an AD to MCI transition would
even mean that there will always be a chance of patients becoming fully recovered from AD,
i.e. returning to a cognitively normal state, an outcome that cannot be supported at present.
However, it should be noted that incorporating an AD to MCI transition in the model would
have a negligible effect on the output due to the small chance of this transition happening. A
small number of patients in ADNI also transitioned from CN directly to AD (3 patients in
yearly assessments across the ten-year cohort). These transitions have also been attributed to
potential misclassifications of patients and not been incorporated into the model (see [59]). A
schematic diagram of the model developed is presented in Fig 1.
Fig 1. Flow diagram of possible transitions between the different states of the Markov model. Individuals can be in one of the following states: Cognitively Normal,
Mild Cognitive Impairment, Alzheimer’s Disease and Withdrawal. Arrows indicate possible transitions between the states. pA,B represents the probability of moving from
state A to state B. The estimated distributions of the average one-year transition probabilities from the ADNI cohort dataset are presented.
https://doi.org/10.1371/journal.pone.0190615.g001
Modelling Alzheimer’s disease
PLOS ONE | https://doi.org/10.1371/journal.pone.0190615 January 29, 2018 4 / 19
Transition probabilities
For the estimation of the transition probabilities between the different states we followed a
piecewise approach. We divided the observation period into one-year intervals and calculated
the transition probabilities in each of these intervals (in ADNI, data exists for a total of 10
years). The probabilities of transitioning between states were estimated independently for each
time interval, and it was assumed that the process is temporarily homogeneous within these
intervals, i.e. the transition probabilities were assumed constant within each of the time
intervals.
Let pSi;SjðtÞ be the transition probability to state Sj at time t given that at time t − 1 the state
is Si, where i, j 2{1, 2,. . ., K} and Si, Sj 2S. S is the state space of the Markov Chain and K is the
number of states. The maximum likelihood estimate of the transition probability pSi ;SjðtÞ is
given by
pSi;Sj tð Þ ¼
tSi;SjðtÞ
PK
l¼1tSi ;SlðtÞ
; ð1Þ
where tSi ;SjðtÞ‘ is the number of transitions from Si (at time t – 1) to Sj (at time t).
PK
j¼1pSi;Sj ¼ 1
for all i.
In order to assess the uncertainty of estimates of each transition probability we used the
bootstrap method [60, 61]. With this method, a number of possible cohort datasets are gener-
ated to develop a range of possible transition matrices. Specifically, for each time interval new
sets of transitions are generated by sampling with replacement from the original set of transi-
tions (the number of transitions in the generated samples is the same as the total number of
transitions in the observational study). Combining all the bootstrapped transition matrices we
derive an approximation of the sampling distribution [61]. To smooth the distributions of the
transition probabilities we fitted a Normal-distribution using the maximum likelihood estima-
tion method.
The accurate estimation of transition probabilities is particularly challenging, mainly due to
the heterogeneity of the data, the infrequent observations on the same patient, and missing
data points [62]. It should be noted that although the total number of individuals in the study
that we used is relatively large (1624 individuals, see subsection ‘Dataset used’), this number
decreases significantly over follow-up, either because individuals die or are lost to follow-up. It
is also important to note that our analysis uses follow-up time as opposed to chronological
time, such that those subjects recruited later (into the newer ADNI-GO or ADNI-2 cohorts,
see subsection ‘Dataset used’) will have inherently less follow-up time than those enrolled ini-
tially into the study (ADNI-1). Thus, we naturally lose depth in the number of subjects at later
follow-up times due to recruitment date.
Stochastic simulation
Within the modelling framework described, we numerically simulated the time progression of
the disease in a sample of individuals in a clinical trial. As an example, in this preliminary
study the development and progression of the disease was simulated in a general population of
1000 individuals for duration of up to 10 years. The trial duration was discretised into uniform
steps. The time-step was defined to be one-month. At the beginning of each simulation, a
value for each transition probability was assigned to each individual in the trial. The value was
drawn at random from the respective distribution of the average one-year transition probabil-
ity. In each time-step in the simulation (same for all individuals), each individual moved inde-
pendently from one state to another state with the defined transition probability. The state of
Modelling Alzheimer’s disease
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each individual was updated synchronously. For each numerical simulation we performed 104
realisations. We focused on the proportion of AD cases over time. We are mainly interested in
the effect of potential preventative treatments, before the occurrence of AD clinical symptoms.
For this reason, we considered optimistic treatments focusing on the case where at the begin-
ning of the process all individuals are cognitively normal. The other extreme where all individ-
uals are initially at the MCI state was also considered. It should be noted that, given the
assumption that AD is a progressive disorder, and thus AD is an irreversible state, including a
number of AD individuals in the initial population would have the same effect as removing
these individuals completely from the process.
The simulator was developed in MATLAB (R2017b). The computer code can be obtained
from the authors upon request.
Impact of interventions
Interventions were applied at different time points of the process. In our analysis we focused
on treatments that, irrespective of their specific action, reduce the probability of transitioning
from state X to a more severe state Y by a proportion EX,Y 2 (0,1). Despite the nature of the
dataset we used, we focused on preventative treatments that are administered to a sample of
cognitively normal individuals in order to reduce the probability of transitioning to MCI and
later from MCI to AD. The same treatments were also assessed in a sample consisting of only
MCI individuals. We also simulated clinical trials to evaluate the effect of treatments that are
administered to a sample of only cognitively normal individuals, but the treatment becomes
effective only at the MCI state and reduces the probability of developing AD. The effect of a
treatment that reduces the probability of transitioning from CN to MCI has a negligible effect
when administered to individuals that have already reached the MCI state. To investigate the
impact of treatments that might not be effective beyond a point, as may happen, for example,
due to severe neuronal degeneration, we also considered treatments that are administered
before the MCI onset to reduce only the probability of developing MCI, i.e. they are no longer
effective beyond the MCI state. Indeed, the model also allows the consideration of the effec-
tiveness of treatments that might vary with time, but we did not consider this scenario in the
current study. All the treatment effects were assumed to be homogeneous between individuals.
We focused on the ideal scenario where treatments have an immediate effect, but we also
considered cases where there are time delays, which may refer either to delays in the adminis-
tration of treatments that are immediately effective or delays before treatments that are admin-
istered at the beginning of the trial start to be effective. Indeed, if a clinical trial involving ideal
treatments which have an immediate effect and their effectiveness is not reduced over time is
unsuccessful, we expect that clinical trials of less effective treatments (example, clinical trials of
treatments which have delayed and/or time-decaying effects) will also be unsuccessful. We
assessed the impact of interventions on the proportion of AD cases over time. The effect of a
treatment at a specific time point is defined as the mean difference between the proportion of
AD cases in the untreated and treated groups. Other potential endpoints that could be studied
using the model include the incidence proportion of AD cases, the expected time spent in a
disease state, and the expected time and probability to reach a specific state from any other
state. Information for each of these endpoints is generated in the simulation.
For every simulation output we present the predicted value of the proportion of AD cases at
the end of a 5- and a 10-year trial under different intervention scenarios. We calculated the
95% credible interval of the distribution of the proportion of AD cases and the standard devia-
tion. Although outside the scope of the current study, it should be noted that the results of
such simulation exercises could also be used as prior information required for sample size
Modelling Alzheimer’s disease
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calculations before the conduct of a clinical trial. For every case, we performed a hypothesis
test for the equality of two binomial proportions, the proportions of AD cases in the treated
and untreated groups, i.e. we tested whether the difference of the two proportions is equal to 0.
A two-tailed test was performed and statistical significance was calculated using a 95% confi-
dence level.
Dataset used
For the development of the Markov model and the estimation of the model parameters we
used data obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database
(adni.loni.usc.edu, last downloaded 2016/10/31). The ADNI was launched in 2003 as a public-
private partnership, led by Principal Investigator Michael W. Weiner, MD. The primary goal
of ADNI has been to test whether serial magnetic resonance imaging (MRI), positron emission
tomography (PET), other biological markers, and clinical and neuropsychological assessment
can be combined to measure the progression of mild cognitive impairment (MCI) and early
Alzheimer’s disease (AD). For up-to-date information, see www.adni-info.org.
The dataset used is a longitudinal observational study consisting of 1737 individuals (from
the ADNI-1, ADNI-GO, and ADNI-2 protocols), 106 of which were categorised as ‘Significant
Memory Concern’ (SMC) at baseline and excluded from our analysis. In addition, there were
7 individuals that had only a screening visit and they were also excluded. Therefore, in the
present study, we analysed data from 1624 participants. The characteristics of the individuals
in the dataset considered are presented in Supporting Information, S1 Table. The maximum
duration for which a participant in the study has been followed up is 10 years. It should be
noted that in the original dataset, individuals in the MCI state are further classified as ‘Early
MCI’ (EMCI) and ‘Late MCI’ (LMCI). However, in this analysis we combined the two MCI
subtypes.
The status of individuals was assessed only at the distinct time points considered in the
model. The number of transitions between the states of the Markov model at each time point
is presented in Supporting Information, S2 Table.
Results
Fig 1 illustrates the distributions of the average one-year transition probabilities (for the
parameters of the fitted Normal distributions see Table 1). Fig 2, Fig 3 and S1 Fig show the out-
put of stochastic simulations (expected proportion of AD cases over time in a general popula-
tion of 1000 individuals) in the untreated and treated groups under different intervention
scenarios. In all the examples presented in these figures we assumed that individuals are ini-
tially at the CN state. S2 Fig shows the output of simulations for the case where treatments
reduce the probability of transitioning from CN to MCI and from MCI to AD, and all
Table 1. Fitted normal distributions for the average one-year transition probabilities between the states of the Markov model. SD: standard deviation.
Average
one-year transition
probabilities
CN!MCI MCI!CN MCI!AD
mean = 0.0432,
SD = 0.0055
mean = 0.0218,
SD = 0.0044
mean = 0.0954,
SD = 0.0090
CN!Withdrawal MCI!Withdrawal AD!Withdrawal
mean = 0.0372,
SD = 0.0046
mean = 0.0528,
SD = 0.0057
mean = 0.1765,
SD = 0.0127
CN!CN MCI!MCI AD!AD
mean = 0.9197,
SD = 0.0070
mean = 0.8300,
SD = 0.0108
mean = 0.8235,
SD = 0.0127
https://doi.org/10.1371/journal.pone.0190615.t001
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individuals are initially at the MCI state. In each of the above figures, the uncertainty in the
output of the stochastic simulations in both the treated and untreated groups is also illustrated.
Fig 2. Output of stochastic simulations: The expected proportion of AD cases over time and the effect of treatments that reduce the transition probabilities
pCN,MCI and pMCI,AD in a sample of CN individuals. The expected proportion of AD cases over time in the untreated group is presented by the solid line. The
expected proportions after the administration of potential treatments that reduce the transition probabilities pCN,MCI and pMCI,AD by a proportion ECN,MCI and EMCI,AD,
respectively, are presented by the dashed lines. (A) ECN,MCI = 0.2, EMCI,AD = 0.2, (B) ECN,MCI = 0.4, EMCI,AD = 0.4, (C) ECN,MCI = 0.6, EMCI,AD = 0.6, (D) ECN,MCI = 0.8,
EMCI,AD = 0.8. The value of E can be interpreted as the efficacy of the candidate treatment, with E = 0 implying no efficacy and E = 1 a 100% efficacy which stops
progression. The ‘shaded area’ represents the 95% credible interval of the distribution of the proportion of AD cases. At the beginning of the trial all individuals are at
the CN state. The population size in each group is N = 1000.
https://doi.org/10.1371/journal.pone.0190615.g002
Modelling Alzheimer’s disease
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The expected values of the proportion of AD cases at the end of a 5- and a 10-year simulated
trial where all individuals are initially cognitively normal are provided in S3 Table. In S4 Table
Fig 3. Output of stochastic simulations: The expected proportion of AD cases over time and the effect of treatments that reduce the transition probability pMCI,AD
in a sample of CN individuals. The expected proportion of AD cases over time in the untreated group is presented by the solid line. The expected proportions after the
administration of potential treatments that reduce the transition probability pMCI,AD by a proportion EMCI,AD are presented by the dashed lines. (A) EMCI,AD = 0.2, (B)
EMCI,AD = 0.4, (C) EMCI,AD = 0.6, (D) EMCI,AD = 0.8. The value of E can be interpreted as the efficacy of the candidate treatment, with E = 0 implying no efficacy and E = 1
a 100% efficacy which stops progression. The ‘shaded area’ represents the 95% credible interval of the distribution of the proportion of AD cases. At the beginning of the
trial all individuals are at the CN state. The population size in each group is N = 1000.
https://doi.org/10.1371/journal.pone.0190615.g003
Modelling Alzheimer’s disease
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we present the results obtained at the end of a 5-year simulated trial for the cases where all
individuals are initially at the MCI state. For each case, the 95% credible interval and the stan-
dard deviation are also presented. In S5 and S6 Tables we present the p-values of the hypothesis
tests for the equality of the proportions of AD cases in the untreated and treated groups under
the different intervention scenarios that have been investigated.
It is observed that although treatments might be effective in reducing the chance of develop-
ing AD, due to the high uncertainty it might be difficult to assess their real effectiveness in a
clinical trial. In particular, it is remarkable that in the sample of cognitively normal individuals
alone, the simulation suggests that in a clinical trial of duration of five years, it is likely that the
true efficacy of a treatment will not be detected even if the treatment has moderate efficacy
(Fig 2, S3 and S5 Tables). As expected, if all the participants are initially at the CN state, a dif-
ference between the untreated and the treated group becomes even more challenging if the
treatment is effective only when individuals are at the MCI state (Fig 3, S3 and S5 Tables). In
particular, in a sample of cognitively normal individuals, treatments that reduce both the tran-
sition probability of moving from CN to MCI and the probability of moving from MCI to AD
are the most effective, followed by treatments that reduce only the probability of transitioning
from CN to MCI and then the treatments that reduce the probability of developing AD from
the MCI state. Increasing the duration of the trial and the population size improves the
chances of clinical success in all cases (see for example S3 and S5 Tables). The efficacy of a
treatment that reduces the probability of transitioning to more severe states may be more likely
to be detected in a trial where all individuals are initially at the MCI state (S2 Fig, S4 and S6
Tables). However, the proportion of AD cases at the end of such a trial is much higher. As
mentioned earlier, in the analysis performed we showed that the effect of a treatment that
reduces the probability of moving from CN to MCI state is negligible when it is administered
to MCI individuals.
Fig 4 illustrates the impact of time delays, before the treatment starts to be effective, on the
proportion of AD cases at the end of a 5-year simulated trial. The treatment is administered
to reduce the probabilities of transitioning to more severe states (pCN,MCI only, pMCI,AD only,
Fig 4. The expected proportion of AD cases at the end of a 5-year trial and the impact of time delays in the activation of various treatments in a sample of CN
individuals. Treatments that reduce the transition probabilities (A) pCN,MCI only, (B) pMCI,AD only, (C) pCN,MCI and pMCI,AD, by a proportion 0.5 are effective after some
time delay. Circles represent the expected proportion of AD cases at the end of a 5-year trial and the error bars the 95% credible interval. At the beginning of the trial all
individuals are at the CN state. The population size in each group is N = 1000.
https://doi.org/10.1371/journal.pone.0190615.g004
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pCN,MCI and pMCI,AD). The impact of such delays on the proportion of AD cases at the end of a
10-year trial in the same scenario is illustrated in S3 Fig. In both Fig 4 and S3 Fig all individuals
are initially cognitively normal. S4 Fig shows the impact of time delays on the effect of a treat-
ment that reduces the transition probabilities from CN to MCI and from MCI to AD when the
initial population consists of only MCI individuals. Fig 4, as well as S3 and S4 Figs, can also be
thought of as the case where there is a period of delay before the administration of treatments
that are immediately effective. Such delays influence the population distribution at the time of
treatment administration; the initial number of CN individuals decreases and the number of
MCI and AD individuals increases. It is shown that treatments administered to CN individuals
are likely to be more effective in slowing AD progression if they are administered at the begin-
ning of the study (t = 0) to reduce the probabilities of moving to MCI and later to AD state
(see Fig 4, S3 and S5 Tables). However, the impact of time delays is more pronounced in the
cases where treatments given to CN individuals reduce their chance of transitioning to the
MCI state (but see S4 Fig). This is partly due to the fact that delays in the ‘activation’ of the
treatment result in a reduction in the number of CN individuals who can benefit from the
treatment, as a consequence of disease development between the initiation of the study and
treatment activation. Consequently, after some delay, treatments administered to CN individ-
uals to reduce the probability of developing AD from the MCI state may be more effective
than treatments administered to CN individuals to reduce only the probability of moving to
the MCI state. Hence, in a clinical trial the specific time of intervention is crucial.
Discussion
Using the ADNI dataset, we developed a basic framework for the simulation of the develop-
ment and progression of AD in a clinical trial to facilitate the assessment of the effect of poten-
tial candidate treatments. Treatments slow the transition to a more severe state, and thus
disease progression. This reduction in the progression rate of the disease can be associated
with a significant decrease in the incidence of AD, increase in the duration of individuals’
independence and the time until institutionalisation, and concomitantly a significant decrease
in the costs of care. It is interesting to note that if such interventions could delay both disease
onset and disease progression by even one year, the global prevalence of AD could decrease by
almost 9.2 million, by the year 2050 [3].
It has been demonstrated that the chance of identifying the true treatment effect may be chal-
lenging due to the high uncertainty in the clinical trial outcome, even if the treatment has high
efficacy. This can be one of the dominant causes of trial failure of AD treatments. The high
uncertainty, which can be illustrated by the output of the simulations, can be attributed partly
to the sparsity and heterogeneity of the available data, and the high variance in the measure-
ments of markers that have been used for the classification of individuals in the different disease
states. The simple criteria used for the classification of individuals, such as the performance on
cognitive tests, and potential associated measurement error, may influence the correct diagnosis
and could be an important reason of the presence of the high variability. Other reasons that can
introduce variability in the measurements, both within and between individuals, and influence
the diagnosis of the actual clinical stage include underlying medical conditions such as the pres-
ence of depression or psychosis, inter-clinician differences in application of diagnostic criteria,
and resistance to cognitive decline due to cognitive reserve [42, 47, 63–65]. As some of these fac-
tors can significantly contribute to variance in the model parameters representing disease pro-
gression, they should potentially be considered as covariates in extended models.
It should be noted that, due to the nature of the ADNI data used in this study, our outputs
may not reflect the progression and impact of the disease in the general population, and indeed
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the output in prevention clinical trials considered here. Participants in this dataset have been
selected to mimic that of a population that would be recruited for a clinical trial of a potential
AD-drug, such as from memory assessment clinics [66, 67]. For example, as observed in Sup-
porting Information, S1 Table, in the dataset used in this study there is a high proportion of
ApoE ε4 carriers, which is a significant genetic risk factor of AD. Thus, these individuals are at
higher risk of developing the disease, creating significant selection bias issues. In addition, in
the model we assumed long preclinical and prodromal AD stages and ADNI dataset is not suf-
ficient to support this silent ‘incubation period’. Due to the nature of the data, we also believe
that the real effect of hypothetical preventative treatments, as assessed in the current study, is
underestimated, as CN individuals in ADNI move faster to the MCI state than expected in the
general population. However, all this should not limit the applicability of the model and the
major outputs of this work which illustrate the usefulness of clinical trial simulations in AD
therapy area, and how the high variability in measurements could mask the true efficacy of
potential AD treatments.
Despite the nature of AD and problems with the available data, the Markov model is a pow-
erful tool for predicting the development and progression of the disease and the assessment of
the impact of potential treatments in clinical trials. Ideally, the model described in this paper
should be extended so that there are more disease states, given there is enough information
for the derivation of reliable estimates of the model parameters. The model should also be
extended for the estimation of covariate effects of risk factors on transitions among states and
concomitantly on disease progression. Such covariates could include age, genetic background
(for example presence/absence of the apolipoprotein ε4 (APOE ε4) genotype), gender and
education, all of which are important risk factors for AD. Other factors, such as family history,
capability, lifestyle (e.g. alcohol consumption), social status, health and environment can also
be influential [68]. Adding such heterogeneity will be described in a subsequent publication. It
would also be interesting to incorporate into the model changes in cognitive markers and bio-
markers, such as beta-amyloid and total-tau [69], as well as MRI markers, even though the pre-
cise estimates of the transition probabilities over time, conditional on the levels of these
markers, might be difficult using the current data.
Clinical trials are difficult to conduct and very expensive if carried out in large samples of
patients observed over many years. Modelling and simulating AD trials are relatively low cost
activities and they can be a powerful tool for improving the design of the actual clinical trials
and increase the chances of the accurate assessment of treatment efficacy [70]. Improving the
quality of the data is clearly essential for the determination of the importance of variance in
clinical trials. The reduction of the variance in currently employed measures (whether bio-
markers, brain scans or cognitive scores) will improve trial design, facilitate detecting a signal
in the trial, shorten the trial times and reduce the number of patients enrolled. Ideal datasets
should include frequent sampling and repeated assessments for the same individual [71]. Uti-
lising the growing number of available AD datasets from many different countries, and per-
forming systematic and standardised analyses, it should be possible to provide substantial
information for improving clinical trial design [72]. However, extra caution will be needed
when working with the different datasets. Among the available studies there is a variation in
the diagnostic tools, in the markers measured and measurement methods used. There is also a
little agreement on the definition of the disease states and selection criteria as well as the size
and demographic characteristics of the samples. Pooling and standardisation of clinical trial
data, as well as standardisation of the methods employed in future studies, will facilitate better
prediction of disease course and allow for better interpretation of model predictions. It will
help in the identification of the sources of variance, and consequently it will facilitate progress
towards the precise assessment of new prophylactic and therapeutic treatments of AD.
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